GB Sciences (GBLX) 10-K 14 Jul 23 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2023	Jul. 14, 2023	Sep. 30, 2022
Document Information [Line Items]
Entity Central Index Key	0001165320
Entity Registrant Name	GB SCIENCES INC
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	000-55462
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	59-3733133
Entity Address, Address Line One	9205 W. Russell Road, Suite 240
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89148
City Area Code	866
Local Phone Number	721-0297
Title of 12(g) Security	Common Stock $.0001 Par Value
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 11,300,000
Entity Common Stock, Shares Outstanding		381,872,561
Auditor Firm ID	5036
Auditor Location	Margate, Florida
Auditor Name	ASSURANCE DIMENSIONS

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Mar. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 109,912	$ 233,893
Prepaid expenses and other current assets	199,592	93,933
TOTAL CURRENT ASSETS	309,504	327,826
Intangible assets, net of accumulated amortization and impairment of $2,390,297 and $104,201 at March 31, 2023 and 2022, respectively	42,819	2,222,074
TOTAL ASSETS	352,323	2,549,900
CURRENT LIABILITIES:
Accrued interest	346,806	384,769
Accrued liabilities	75,628	9,627
Notes and convertible notes payable, net of unamortized discount of $41,230 and $1,765 at March 31, 2023 and 2022, respectively	1,396,077	987,565
Income tax payable	958,455	896,495
TOTAL CURRENT LIABILITIES	4,759,706	3,935,464
Convertible notes payable, net of unamortized discount of $0 and $99,489 at March 31, 2023 and 2022, respectively	0	397,308
TOTAL LIABILITIES	4,759,706	4,332,772
Commitments and contingencies (Note 11)
STOCKHOLDERS' DEFICIT:
Common Stock, $0.0001 par value, 950,000,000 shares authorized, 381,872,561 and 325,037,557 outstanding at March 31, 2023 and 2022, respectively	38,187	32,504
Additional paid-in capital	104,259,745	102,764,746
Accumulated deficit	108,705,315	104,580,122
TOTAL STOCKHOLDERS' DEFICIT	(4,407,383)	(1,782,872)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	352,323	2,549,900
Nonrelated Party [Member]
CURRENT LIABILITIES:
Accounts payable	1,861,829	1,657,008
Related Party [Member]
CURRENT LIABILITIES:
Accounts payable	$ 120,911	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Intangible assets, accumulated amortization	$ 2,390,297	$ 104,201
Unamortized discount, current	41,230	1,765
Unamortized discount, noncurrent	$ 0	$ 99,489
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	950,000,000	950,000,000
Common stock, shares issued (in shares)	381,872,561	325,037,557
Common stock, shares outstanding (in shares)	381,872,561	325,037,557

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Sales revenue	$ 0	$ 0
Cost of goods sold	0	0
Gross profit (loss)	0	0
General and administrative expenses	1,672,281	1,868,734
LOSS FROM OPERATIONS	(1,672,281)	(1,868,734)
OTHER INCOME (EXPENSE)
Gain on extinguishment of debt	0	22,405
Gain on deconsolidation	0	5,206,208
Interest expense	(178,652)	(474,768)
Loss on impairment of note receivable	0	(3,025,000)
Loss on impairment of capitalized patent costs	(2,374,261)	0
Loss on disposal	0	(15,639)
Other income	100,000	9,000
Total other income/(expense)	(2,452,913)	1,722,206
LOSS BEFORE INCOME TAXES	(4,125,194)	(146,528)
Income tax expense (Note 8)	0	0
LOSS FROM CONTINUING OPERATIONS	(4,125,194)	(146,528)
Net loss from discontinued operations (Note 4)	0	(384,345)
NET LOSS	(4,125,194)	(530,873)
Net loss attributable to common stockholders of GB Sciences, Inc. - basic and diluted
Continuing operations, basic	(4,125,194)	(146,528)
Discontinued operations, basic	0	(384,345)
Net loss	$ (4,125,194)	$ (530,873)
Net loss per common share – basic and diluted
Continuing operations (in dollars per share)	$ (0.01)	$ 0
Discontinued operations (in dollars per share)	0	0
Net loss (in dollars per share)	$ (0.01)	$ 0
Weighted average common shares outstanding - basic and diluted (in shares)	357,721,189	317,621,942

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Compensation Warrant [Member] Common Stock [Member]	Compensation Warrant [Member] Additional Paid-in Capital [Member]	Compensation Warrant [Member] Retained Earnings [Member]	Compensation Warrant [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Mar. 31, 2021					315,340,411
Balance at Mar. 31, 2021					$ 31,534	$ 102,380,770	$ (103,886,232)	$ (1,473,928)
Stock issued for warrant exercises (in shares)	7,601,813				2,095,333
Stock issued for warrant exercises, net of brokerage fees	$ 760	$ 75,308	$ 0	$ 76,068	$ 210	56,184	0	56,394
Inducement dividend from warrant exercises					0	163,017	(163,017)	0
Share-based compensation expense						60,667		60,667
Stock options issued for preparing capitalized patent applications					0	28,800	0	28,800
Net income (loss)					$ 0	0	(530,873)	(530,873)
Balance (in shares) at Mar. 31, 2022					325,037,557
Balance at Mar. 31, 2022					$ 32,504	102,764,746	(104,580,122)	(1,782,872)
Share-based compensation expense					0	17,333	0	17,333
Stock options issued for preparing capitalized patent applications								0
Net income (loss)					$ 0	0	(4,125,194)	(4,125,194)
Stock issued in private placement, net of brokerage fees (in shares)					56,835,004
Stock issued in private placement, net of brokerage fees					$ 5,683	1,477,666	0	1,483,350
Balance (in shares) at Mar. 31, 2023					381,872,561
Balance at Mar. 31, 2023					$ 38,187	$ 104,259,745	$ (108,705,315)	$ (4,407,383)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows	12 Months Ended
	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
OPERATING ACTIVITIES:
Net loss	$ (4,125,194)	$ (530,873)
Loss from discontinued operations	0	(384,345)
Net loss from continuing operations	(4,125,194)	(146,528)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	61,660	70,488
Stock-based compensation	17,333	60,667
Amortization of debt discount and beneficial conversion feature	60,024	356,340
Gain on extinguishment	0	(22,405)
Loss on disposal of assets	0	15,639
Loss on impairment of note receivable	0	3,025,000
Loss on impairment of capitalized patent costs	2,374,261	0
Gain on deconsolidation	0	(5,206,208)	$ (5,206,208)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(105,659)	162,318
Accounts payable	(20,195)	821,253
Accrued liabilities	66,001	(948,319)
Accrued interest	(37,963)	118,286
Accrued income taxes	61,960	0
Indebtedness to related parties	120,911	(84,913)
Net cash used in operating activities of continuing operations	(1,526,861)	(1,778,382)
Net cash used in operating activities of discontinued operations	0	(87,772)
Net cash used in operating activities	(1,526,861)	(1,866,154)
INVESTING ACTIVITIES:
Proceeds from sale of Nevada Subsidiaries	0	1,648,772
Cash paid for capitalized patent costs	(31,650)	(200,000)
Net cash provided by/(used in) investing activities of continuing operations	(31,650)	1,448,772
Net cash provided by/(used in) investing activities of discontinued operations	0	1,567
Net cash provided by/(used in) investing activities	(31,650)	1,450,339
FINANCING ACTIVITIES:
Proceeds from warrant exercises	0	138,728
Proceeds from convertible notes payable	0	50,000
Gross proceeds from sale of common stock, net of brokerage fees	1,483,350	0
Principal payment on notes payable	(48,820)	(575,000)
Net cash provided by/(used in) financing activities of continuing operations	1,434,530	(392,538)
Net cash used in financing activities of discontinued operations	0	(103,387)
Net cash provided by/(used in) financing activities	1,434,530	(495,925)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(123,981)	(911,740)
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	233,893	1,145,633
CASH AND CASH EQUIVALENTS AT END OF YEAR	109,912	233,893
Less: cash and cash equivalents classified as discontinued operations	0	0
CASH AND CASH EQUIVALENTS AT END OF YEAR FROM CONTINUING OPERATIONS	109,912	233,893
Cash paid for interest	0	0
Cash paid for income tax	0	0
Noncash investing and financing transactions:
Noncash additions for capitalized patent costs	246,132	0
Note receivable from sale of Nevada Subsidiaries	0	3,025,000
Extinguishment of debt and accrued interest owed to purchasers of Nevada Subsidiaries and purchasers' affiliates	0	2,612,854
Extinguishment of accrued management fees payable to purchaser of Nevada Subsidiaries	0	850,000
Depreciation capitalized in inventory (discontinued operations)	0	349,015
Patent acquisition costs capitalized in intangible assets	0	347,617
Stock options issued for preparing capitalized patent applications	0	28,800
Inducement dividend from warrant exercises	$ 0	$ 163,017

Note 1 - Background and Nature

Note 1 - Background and Nature of Operations	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	Note 1 Business GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) is a phytomedical research and biopharmaceutical drug development company engaged in creating patented formulations of plant-inspired, complex therapeutic mixtures for the prescription drug market that target a variety of medical conditions. The Company is engaged in the research and development of plant-based medicines and plans to produce plant-inspired, complex therapeutic mixtures based on its portfolio of intellectual property. The Company is engaged in the research and development of plant-based medicines, primarily cannabinoid-inspired medicines, with virtual operations in North America and Europe. GBSGB’s assets include a portfolio of intellectual property containing both proprietary cannabinoid-containing formulations and our AI-enabled drug discovery platform, as well as critical research contracts and key supplier arrangements. GBSGB’s intellectual property covers a range of medical conditions and several programs are in the pre-clinical animal stage of development including Parkinson’s disease, neuropathic pain, and cardiovascular therapeutic programs. GBSGB runs a lean drug development program and takes effort to minimize expenses, including personnel, overhead, and fixed capital expenses through strategic partnerships with Universities and Contract Research Organizations (“CROs”). GBSGB’s intellectual property portfolio includes six 18 one 55 We were incorporated in the State of Delaware on April 4, 2001, March 28, 2008, On April 4, 2014, December 12, 2016, Effective April 8, 2018, August 15, 2019, 400,000,000 March 09, 2023, Recent Developments Intellectual Property Portfolio In the past year GBLX/GBSGB’s foreign patents for plant-based treatments of serious disorders were allowed in different countries, expanding our patent protections as follows. On February 3, 2023, first $8.8 2026, December 1, 2022, December 15, 2022, February 20, 2023, March 9, 2023, No. 16/878,295. April 25, 2023, In 2021, October 2021. July 2021. September 2021, Divestiture of Nevada Cannabis Operations On March 24, 2020, On August 10, 2020, 483 October 23, 2017 ( 5 The closing of the Teco and Nopah sales was contingent upon the successful transfer of the Nevada cultivation and production licenses. On December 14, 2021, December 31, 2021. no As consideration for the membership interests, the Company received cash payments of $1,648,772 (including $400,000 in advance payments received during the nine December 31, 2021), 13

Note 2 - Going Concern

Note 2 - Going Concern	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	Note 2 The Company’s consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $108,705,315 at March 31, 2023. March 31, 2023, March 31, 2022. March 31, 2023, March 31, 2022. one Management has been able, thus far, to finance the losses through a public offering, private placements of debt and equity, and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no In view of these conditions, the Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying consolidated financial statements do not may

Note 3 - Basis of Presentation

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 3 Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. The subsidiaries of the Company are: Continuing Operations: GBS Global Biopharma, Inc. ECRX, Inc. The PhAROS Institute, LLC Discontinued Operations: GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC GB Sciences Nopah, LLC Intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, collectability of notes receivable, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may Discontinued Operations See Note 4. Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three - Level 1 - Level 2 - Level 3 The carrying value of cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value, primarily due to the short-term nature of the instruments. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three March 31, 2023 2022. Indefinite and Definite-Lived Intangible Assets Capitalized costs related to our indefinite-lived intangible assets consisted primarily of the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. Intangible assets also historically included the acquisition cost of a cannabis production license with an indefinite life. We historically amortized our finite-lived intangible assets, which consisted of granted patents, over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. We review all of our intangible assets for impairment indicators throughout the year. Impairment testing for indefinite-lived intangible assets is performed at least annually and we perform testing for definite-lived intangible assets whenever impairment indicators are present. If we determine that the fair value is less than the carrying value of these assets during testing, we record impairment losses equal to the difference between the carrying value of the asset and the fair market value of the asset. As of March 31, 2023, March 31, 2023 350 30 35. At March 31, 2023, January 2038 May 2039. March 31, 2023 2022, March 31, 2023. There were 10 United States patent applications that are pending as of March 31, 2023, March 31, 2023. March 31, 2023. Operating Lease Right-of-Use Asset and Liability The Company determines if an arrangement is a lease at inception and had lease agreements for office facilities, equipment, and other space and assets with non-cancelable lease terms which were primarily components of discontinued operations. Certain real estate and property leases, and various other operating leases are measured on the balance sheet with a lease liability and right-of-use asset ("ROU"). ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the New Lease Standard. Lease payments do not Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of twelve not At March 31, 2023 March 31, 2022, no March 31, 2022. Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets: 3 8 not At March 31, 2023 March 31, 2022, no March 31, 2022. Long-Lived Assets Property and equipment comprised a significant portion of our total assets from discontinued operations. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, Debt with Conversion and Other Options 00 27, Application of Issue No. 98 5 first 718 Compensation Stock Compensation The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source is part of discontinued operations and derives from sales of cannabis and cannabis products, distinct physical goods. Under ASC 606, may may one 606 not Research and Development Costs Research and development costs are expensed as incurred. During the years ended March 31, 2023 2022, Equity-Based Compensation The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 718 no may may may Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company operated in the State-licensed cannabis industry until the December 31, 2021 13 280E “280E” 280E, no not may not 280E. Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the year. The Company had 167,252,135 and 118,594,624 potentially dilutive common shares at March 31, 2023 2022, not Recent Accounting Pronouncements Standards Recently Adopted In May 2021, No. 2021 04, 2021 04 April 1, 2022. April 1, 2022 not Standards Not On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2023. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not

Note 4 - Discontinued Operation

Note 4 - Discontinued Operations	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	Note 4 Discontinued Operations Discontinued operations comprise those activities that were disposed of during the period, or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. The Company has included its subsidiaries GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC in discontinued operations due to the sale of the Company's Nevada Subsidiaries (Note 13 The assets and liabilities associated with discontinued operations included in our consolidated balance sheets as of March 31, 2023 2022 March 31, 2023 March 31, 2022 Continuing Discontinued Nevada Subsidiaries Total Continuing Discontinued Nevada Subsidiaries Total ASSETS CURRENT ASSETS Cash $ 109,912 $ - $ 109,912 $ 233,893 $ - $ 233,893 Prepaid and other current assets 199,592 - 199,592 93,933 - 93,933 TOTAL CURRENT ASSETS 309,504 - 309,504 327,826 - 327,826 Intangible assets, net 42,819 - 42,819 2,222,074 - 2,222,074 TOTAL ASSETS $ 352,323 $ - $ 352,323 $ 2,549,900 $ - $ 2,549,900 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,982,740 $ - $ 1,982,740 $ 1,657,008 $ - $ 1,657,008 Accrued interest 346,806 - 346,806 384,769 - 384,769 Accrued liabilities 75,628 - 75,628 9,627 - 9,627 Notes and convertible notes payable, net 935,000 - 935,000 987,565 - 987,565 Convertible notes payable, net 461,077 - 461,077 - - - Income tax payable 958,455 - 958,455 896,495 - 896,495 TOTAL CURRENT LIABILITIES 4,759,706 - 4,759,706 3,935,464 - 3,935,464 Convertible notes payable, net - - - 397,308 - 397,308 TOTAL LIABILITIES $ 4,759,706 $ - $ 4,759,706 $ 4,332,772 $ - $ 4,332,772 The revenues and expenses associated with discontinued operations included in our consolidated statements of operations for the years ended March 31, 2023 2022, 2023 2022 Continuing Discontinued - Nevada Total Continuing Discontinued - Nevada Total Sales revenue $ - $ - $ - $ - $ 3,369,812 $ 3,369,812 Cost of goods sold - - - - (3,072,622 ) (3,072,622 ) Gross profit (loss) - - - - 297,190 297,190 General and administrative expenses 1,672,281 - 1,672,281 1,868,734 264,515 2,133,249 LOSS FROM OPERATIONS (1,672,281 ) - (1,672,281 ) (1,868,734 ) 32,675 (1,836,059 ) OTHER INCOME/(EXPENSE) Gain on extinguishment - - - 22,405 - 22,405 Gain on deconsolidation - - - 5,206,208 - 5,206,208 Interest expense (178,652 ) - (178,652 ) (474,768 ) (302,923 ) (777,691 ) Loss on impairment of note receivable - - - (3,025,000 ) - (3,025,000 ) Loss on impairment of capitalized patent costs (2,374,261 ) - (2,374,261 ) - - - Loss on disposal - - - (15,639 ) - (15,639 ) Other income 100,000 - 100,000 9,000 20,889 29,889 TOTAL OTHER INCOME/(EXPENSE) (2,452,913 ) - (2,452,913 ) 1,722,206 (282,034 ) 1,440,172 NET LOSS BEFORE INCOME TAXES (4,125,194 ) - (4,125,194 ) (146,528 ) (249,359 ) (395,887 ) Income tax expense - - - - (134,986 ) (134,986 ) NET LOSS $ (4,125,194 ) $ - $ (4,125,194 ) $ (146,528 ) $ (384,345 ) $ (530,873 ) Discontinued Operations - Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on aging and subsequent collections. There were no accounts receivable at March 31, 2023 March 31, 2022 13 Discontinued Operations - Inventory We value inventory at the lower of the actual cost of our inventory, as determined using the first first Raw materials consist of supplies, materials, and consumables used in the cultivation and extraction processes. Work-in-progress consisted of live plants and cannabis in the drying, curing, and trimming processes. Finished goods includes completed cannabis flower, trim, and extracts in bulk and packaged forms. There is no March 31, 2023 March 31, 2022, 13 Discontinued Operations - Deposits and Noncurrent Assets There were no deposits and noncurrent assets from discontinued operations at March 31, 2023 2022, Discontinued Operations - Leases The Company evaluates all finance and operating leases, and they are measured on the balance sheet with a lease liability and right-of-use asset (“ROU”) at inception. ROU assets represent the Company’s right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of 12 not The Company's only remaining lease commitment was a finance lease for the Nevada Subsidiaries, which is classified as discontinued operations in the Company's consolidated balance sheet at March 31, 2021. December 31, 2025 December 31, 2030. Finance leases are included in property and equipment (long term assets from discontinued operations), finance lease obligations, short term (current liabilities from discontinued operations), and finance lease obligations, long term (long term liabilities from discontinued operations), on the balance sheet as of March 31, 2021. The right-of-use asset and lease liability were deconsolidated at December 31, 2021 March 31, 2023 2022 March 31, Lease costs (discontinued operations) Classification on the Statements of Operations 2023 2022 Discontinued operations: Finance leases - amortization of ROU assets Loss from discontinued operations $ - $ 116,024 Finance leases - interest on lease liabilities Loss from discontinued operations - 301,796 Operating leases Loss from discontinued operations - - Total lease cost, discontinued operations $ - $ 417,820 Discontinued Operations - 8% Line of Credit dated November 27, 2019 In connection with the Binding Letter of Intent dated November 27, 2019 ( 13 not December 29, 2020, no November 30, 2020. December 31, 2021 March 31, 2021

Note 5 - Notes Payable and Line

Note 5 - Notes Payable and Line of Credit	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 5 Notes Payable and Line of Credit 0% October 23, 2017 On October 23, 2017, one three January 1, 2018. On August 10, 2020, December 31, 2021 December 14, 2021 ( 13 On March 4, 2022, March 4, 2022. We evaluated the modification under the guidance in ASC 470 50 10% March 31, 2022, During the year ended March 31, 2023, March 31, 2023, 8% July 24, 2020 On July 24, 2020, "July 24 may 8% February 28, 2019. July 24 3 July 24 On December 29, 2020, three $325,000 July 24 July 24 one No November 30, 2020. not July 24 March 31, 2021. December 31, 2021, $325,000 March 31, 2021, December 31, 2021, no 13 Summary of Notes Payable and Convertible Notes Payable As of March 31, 2023, As of March 31, 2023 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (as amended), current portion (Note 5) $ - $ - $ - 6% Convertible promissory notes payable (Note 6) 560,000 - 560,000 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 - 325,000 6% Convertible note payable due July 1, 2022 (Note 6) 50,000 - 50,000 6% Convertible promissory notes payable due September 30, 2023 (Note 6) 197,000 (9,475 ) 187,525 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (31,755 ) 218,245 0% Note Payable dated October 23, 2017 (as amended), long term portion (Note 5) 55,307 - 55,307 Total short-term notes and convertible notes payable $ 1,437,307 $ (41,230 ) $ 1,396,077 As of March 31, 2022, As of March 31, 2022 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (as amended), current portion (Note 5) $ 54,330 $ - $ 54,330 6% Convertible promissory notes payable (Note 6) 560,000 - 560,000 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 - 325,000 6% Convertible note payable due July 1, 2022 (Note 6) 50,000 (1,765 ) 48,235 Total short-term notes and convertible notes payable $ 989,330 $ (1,765 ) $ 987,565 6% Convertible promissory notes payable due September 30, 2023 (Note 6) $ 197,000 $ (26,254 ) $ 170,746 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (73,235 ) 176,765 0% Note Payable dated October 23, 2017 (as amended), long term portion (Note 5) 49,797 - 49,797 Total long term convertible notes payable classified as continuing operations $ 496,797 $ (99,489 ) $ 397,308

Note 6 - Convertible Notes

Note 6 - Convertible Notes	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Convertible Debt [Text Block]	Note 6 Convertible Notes March 2017 July 2017 In March 2017, third three March 2017 May 2017, three three In July 2017, third three July 2017 December 2017, three three All notes from the March July 2017 March 31, 2022, $197,000 three September 30, 2023. 10% March 31, 2023, $197,000 March 31, 2023. Three convertible notes totaling $1,060,000 held by the same investor are past maturity and are currently in default. On January 20, 2022, one three not March 31, 2023. 8% Convertible Promissory Note dated February 28, 2019 On February 28, 2019, August 28, 2020, On December 29, 2020, November 30, 2020. December 31, 2021. Upon close of the Teco sale on December 31, 2021, 13 December 2020 $625,000 6% On December 18, 2020, 19 three January 31, 2022 July 1, 2022, December 2023. March 31, 2022, At March 31, 2023, March 31, 2023,

Note 7 - Property and Equipment

Note 7 - Property and Equipment	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 7 Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of the asset or, in the case of leasehold improvements amortized over the lesser of the useful life of the asset or the underlying lease term. At March 31, 2023 March 31, 2022, no 13

Note 8 - Income Taxes

Note 8 - Income Taxes	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 8 Income Taxes The Company files income tax returns in the U.S. federal jurisdiction. The Company operates in the state of Nevada, which does not The Company’s effective tax rate was 0% and 1.8% for the years ended March 31, 2023 2022, A net income tax expense of $61,960 was recorded for the year ended March 31, 2023, March 31, 2018 March 31, 2021 March 31, 2023 March 31, 2022. Because the Company operates in the State-licensed cannabis industry, it is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E. At March 31, 2023 2022 2025 2039. March 31, 2019 no may 50% The provision for income taxes included in discontinued operations is different than would result from applying the U.S. statutory rate to profit before taxes for the reasons set forth in the following reconciliation: 2023 2022 Tax expense/(benefit) computed at U.S. statutory rates $ (182,405 ) $ 691,042 Increases (decreases) in taxes resulting from: IRC Section 280E - 132,063 Other permanent items 9,246 5,526 Change in valuation allowance (756,430 ) 579,861 Adjustments to valuation of deferred tax assets 929,589 (1,408,492 ) Tax return true-up - 58,277 Total provision for income taxes - 58,277 Penalties and interest on prior year tax liabilities 61,960 76,709 Total income tax expense 61,960 $ 134,986 The tax effects of the primary temporary differences giving rise to the Company’s deferred tax assets and liabilities are as follows for the year ended March 31, 2023 2022: 2023 2022 Deferred tax assets: Stock based compensation $ 3,147,724 $ 3,144,084 Net operating loss carryforward 10,934,127 10,816,588 Impairment of long-lived assets 635,250 - Depreciation and Amortization expense (1,369 ) (1,369 ) Other temporary items (209,714 ) (209,714 ) Total deferred tax assets 14,506,018 13,749,589 Less valuation allowance (14,506,018 ) (13,749,589 ) Net deferred tax asset $ - $ - Deferred tax assets are evaluated by considering historical levels of income, estimates of future taxable income and the impact of tax planning strategies. The Company continues to evaluate its deferred tax asset valuation allowance on a quarterly basis. The Company concluded that, as of March 31, 2023, not not The Company believes that the tax positions taken in its tax returns would be sustained upon examination by taxing authorities. The Company files income tax returns in the U.S. federal jurisdiction and other required state jurisdictions. The Company's periodic tax returns filed in 2019

Note 9 - Capital Transactions

Note 9 - Capital Transactions	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Equity [Text Block]	Note 9 Capital Transactions Year Ended March 31, 2023 Sale of Common Stock and Warrants On May 9, 2022 one one one five September 9, 2022, November 30, 2022 March 31, 2023, $1,483,350 one five As the result of the units sold to date under the private placement, the Company will issue its brokers 5,416,834 compensation warrants to purchase one share of the Company's common stock at $0.03 per share for a period of five Employee Option Grant On August 25, 2022, seven one one Year Ended March 31, 2022 On April 1, 2020, $.05 July 18, 2021, September 30, 2021 one three March 31, 2022, On March 1, 2022, During the year ended March 31, 2022, one ten six During the year ended March 31, 2022, March 31, 2022. Warrants Outstanding Presented below is a summary of the Company’s warrant activity, exclusive of warrants held by employees (Note 10 March 31, 2023 2022: Warrants Outstanding Number of Shares Exercise Price Outstanding at March 31, 2021 85,843,036 Warrants issued 2,095,333 0.10 Warrants exercised (9,697,146 ) $0.01 - $0.03 Warrants expired/cancelled (3,116,550 ) 0.60 Outstanding at March 31, 2022 75,124,673 Warrants issued 56,835,004 0.10 Warrants exercised - Warrants expired/cancelled) (9,201,000 ) $0.08 - $0.10 Outstanding at March 31, 2023 122,758,677

Note 10 - Employee Benefit Plan

Note 10 - Employee Benefit Plan	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	Note 10 Employee Benefit Plan Share-Based Employee Compensation On February 6, 2008, 2007 “2007 2007 may 2014 June 30, 2015, 8 April 6, 2018, 2014 2018 October 25, 2018, 8 2018 On September 17, 2021, 2021 "2021 8 2021 2021 March 31, 2023. Compensation Expense For the years ended March 31, 2023 2022, March 31, 2023. Fair Value The closing price of the Company's stock on the date of grant is used as the fair value for issuances of restricted stock. The fair value of stock options granted is estimated as of the grant date using the Black-Scholes option pricing model. The following range of assumptions in the Black-Scholes option pricing model was used to determine fair value: Year Ended March 31, 2023 March 31, 2022 Weighted-average volatility - % 131 % Expected term (in years) - % 10 % Risk-free interest rate - % 1.42 % Expected volatilities used for award valuation are based on historical volatility of the Company's common stock. The risk-free interest rate for periods equal to the expected term of an award is based on Federal Reserve yields for U.S. Treasury securities. Stock Options A summary of employee option activity, including warrants issued to employees, as of March 31, 2023 2022, Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Employee options and warrants Options Price $ Life (years) Value ($) Outstanding at March 31, 2021 17,733,334 $ 0.11 6.80 $ 172,000 Granted - Exercised - Forfeited - Outstanding at March 31, 2022 17,733,334 $ 0.11 5.80 $ - Fully vested and expected to vest at March 31, 2022 17,733,334 $ 0.11 Exercisable at March 31, 2022 15,566,668 $ 0.12 Granted - Exercised - Forfeited - Outstanding at March 31, 2023 17,733,334 $ 0.11 4.80 $ - Fully vested and expected to vest at March 31, 2023 17,733,334 $ 0.11 Exercisable at March 31, 2023 17,733,334 $ 0.11 The table below sets forth nonemployee option activity for the years ended March 31, 2023 2022: Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Nonemployee options Options Price $ Life (years) Value ($) Outstanding at March 31, 2021 5,883,000 $ 0.14 8.11 $ - Granted 600,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2022 6,483,000 $ 0.13 7.31 $ - Fully vested and expected to vest at March 31, 2022 6,483,000 $ 0.13 Exercisable at March 31, 2022 6,483,000 $ 0.13 Granted - Exercised - Forfeited - Outstanding at March 31, 2023 6,483,000 $ 0.13 6.31 $ - Fully vested and expected to vest at March 31, 2023 6,483,000 $ 0.13 Exercisable at March 31, 2023 6,483,000 $ 0.13 Restricted stock awards No March 31, 2023 2022.

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 11 Commitments and Contingencies On April 11, 2022, May 2020. may From time to time, the Company may not The Company is currently involved in projects for which the Company has contracts with vendors and for which the Company has been invoiced approximately $235,000. not 2024, not

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 12 As of March 31, 2023, As of March 31, 2023, During the year ended March 31, 2022, March 31, 2022.

Note 13 - Sale of Membership In

Note 13 - Sale of Membership Interests in Nevada Subsidiaries	12 Months Ended
	Mar. 31, 2023
Nevada Subsidiaries [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 13 On March 24, 2020, On August 10, 2020, 483 October 23, 2017 ( 5 The closing of the Teco and Nopah sales was contingent upon the successful transfer of the Nevada cultivation and production licenses. On December 14, 2021, December 31, 2021. As consideration for the membership interests, the Company received cash payments of $1,648,772 (including $400,000 in advance payments received during the nine December 31, 2021), 5 6 As the result of sale of the Nevada Subsidiaries, the Company recorded a gain on deconsolidation of $5,206,208 on December 31, 2021, December 31, 2021 Cash payments received, including advancements of $400,000 $ 1,648,772 8% Note Receivable due December 31, 2024 3,025,000 Extinguishment of debt and accrued interest due to purchasers and purchasers' affiliates 2,612,854 Extinguishment of accrued management fees due to purchaser 850,000 Total consideration 8,136,626 Carrying amount of assets 7,130,159 Carrying amount of liabilities (4,199,741 ) Net assets deconsolidated 2,930,418 GAIN ON DECONSOLIDATION $ 5,206,208 As the result of sale, the income, assets, and cash flows of GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC have been reclassified as discontinued operations for all periods presented in the Company's consolidated financial statements prior to the sale. Note Receivable from Sale of Teco Subsidiaries The $3,025,000 note receivable from the sale of the Teco Subsidiaries was initially payable as quarterly, interest only payments of $60,500 for the first March 31, 2023, December 31, 2024. The note contains a provision that allows payments of principal and interest due prior to the maturity date to be postponed to the next quarterly payment date if cash flow from the operations of the facility is insufficient to cover the amount of the payment. Several days prior to the first April 1, 2022, April 1, 2022 July 1, 2022 On March 27, 2023, Further in connection with the execution of the March 27, 2023 September 30, 2023, September 30, 2023, September 30, 2023, September 30, 2023

Note 14 - Subsequent Events

Note 14 - Subsequent Events	12 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	Note 14 Subsequent Events Subsequent to March 31, 2023, three June July 2026. Subsequent to March 31, 2023 not

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. The subsidiaries of the Company are: Continuing Operations: GBS Global Biopharma, Inc. ECRX, Inc. The PhAROS Institute, LLC Discontinued Operations: GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC GB Sciences Nopah, LLC Intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, collectability of notes receivable, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations See Note 4.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three - Level 1 - Level 2 - Level 3 The carrying value of cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value, primarily due to the short-term nature of the instruments.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three March 31, 2023 2022.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Indefinite and Definite-Lived Intangible Assets Capitalized costs related to our indefinite-lived intangible assets consisted primarily of the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. Intangible assets also historically included the acquisition cost of a cannabis production license with an indefinite life. We historically amortized our finite-lived intangible assets, which consisted of granted patents, over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. We review all of our intangible assets for impairment indicators throughout the year. Impairment testing for indefinite-lived intangible assets is performed at least annually and we perform testing for definite-lived intangible assets whenever impairment indicators are present. If we determine that the fair value is less than the carrying value of these assets during testing, we record impairment losses equal to the difference between the carrying value of the asset and the fair market value of the asset. As of March 31, 2023, March 31, 2023 350 30 35. At March 31, 2023, January 2038 May 2039. March 31, 2023 2022, March 31, 2023. There were 10 United States patent applications that are pending as of March 31, 2023, March 31, 2023. March 31, 2023.
Lessee, Leases [Policy Text Block]	Operating Lease Right-of-Use Asset and Liability The Company determines if an arrangement is a lease at inception and had lease agreements for office facilities, equipment, and other space and assets with non-cancelable lease terms which were primarily components of discontinued operations. Certain real estate and property leases, and various other operating leases are measured on the balance sheet with a lease liability and right-of-use asset ("ROU"). ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the New Lease Standard. Lease payments do not Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of twelve not At March 31, 2023 March 31, 2022, no March 31, 2022.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets: 3 8 not At March 31, 2023 March 31, 2022, no March 31, 2022.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets Property and equipment comprised a significant portion of our total assets from discontinued operations. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not
Debt, Policy [Policy Text Block]	Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, Debt with Conversion and Other Options 00 27, Application of Issue No. 98 5 first 718 Compensation Stock Compensation The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source is part of discontinued operations and derives from sales of cannabis and cannabis products, distinct physical goods. Under ASC 606, may may one 606 not
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development costs are expensed as incurred. During the years ended March 31, 2023 2022,
Share-Based Payment Arrangement [Policy Text Block]	Equity-Based Compensation The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 718 no may may may
Income Tax, Policy [Policy Text Block]	Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company operated in the State-licensed cannabis industry until the December 31, 2021 13 280E “280E” 280E, no not may not 280E.
Earnings Per Share, Policy [Policy Text Block]	Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the year. The Company had 167,252,135 and 118,594,624 potentially dilutive common shares at March 31, 2023 2022, not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Standards Recently Adopted In May 2021, No. 2021 04, 2021 04 April 1, 2022. April 1, 2022 not Standards Not On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2023. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not

Note 4 - Discontinued Operati_2

Note 4 - Discontinued Operations (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	March 31, 2023 March 31, 2022 Continuing Discontinued Nevada Subsidiaries Total Continuing Discontinued Nevada Subsidiaries Total ASSETS CURRENT ASSETS Cash $ 109,912 $ - $ 109,912 $ 233,893 $ - $ 233,893 Prepaid and other current assets 199,592 - 199,592 93,933 - 93,933 TOTAL CURRENT ASSETS 309,504 - 309,504 327,826 - 327,826 Intangible assets, net 42,819 - 42,819 2,222,074 - 2,222,074 TOTAL ASSETS $ 352,323 $ - $ 352,323 $ 2,549,900 $ - $ 2,549,900 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,982,740 $ - $ 1,982,740 $ 1,657,008 $ - $ 1,657,008 Accrued interest 346,806 - 346,806 384,769 - 384,769 Accrued liabilities 75,628 - 75,628 9,627 - 9,627 Notes and convertible notes payable, net 935,000 - 935,000 987,565 - 987,565 Convertible notes payable, net 461,077 - 461,077 - - - Income tax payable 958,455 - 958,455 896,495 - 896,495 TOTAL CURRENT LIABILITIES 4,759,706 - 4,759,706 3,935,464 - 3,935,464 Convertible notes payable, net - - - 397,308 - 397,308 TOTAL LIABILITIES $ 4,759,706 $ - $ 4,759,706 $ 4,332,772 $ - $ 4,332,772 2023 2022 Continuing Discontinued - Nevada Total Continuing Discontinued - Nevada Total Sales revenue $ - $ - $ - $ - $ 3,369,812 $ 3,369,812 Cost of goods sold - - - - (3,072,622 ) (3,072,622 ) Gross profit (loss) - - - - 297,190 297,190 General and administrative expenses 1,672,281 - 1,672,281 1,868,734 264,515 2,133,249 LOSS FROM OPERATIONS (1,672,281 ) - (1,672,281 ) (1,868,734 ) 32,675 (1,836,059 ) OTHER INCOME/(EXPENSE) Gain on extinguishment - - - 22,405 - 22,405 Gain on deconsolidation - - - 5,206,208 - 5,206,208 Interest expense (178,652 ) - (178,652 ) (474,768 ) (302,923 ) (777,691 ) Loss on impairment of note receivable - - - (3,025,000 ) - (3,025,000 ) Loss on impairment of capitalized patent costs (2,374,261 ) - (2,374,261 ) - - - Loss on disposal - - - (15,639 ) - (15,639 ) Other income 100,000 - 100,000 9,000 20,889 29,889 TOTAL OTHER INCOME/(EXPENSE) (2,452,913 ) - (2,452,913 ) 1,722,206 (282,034 ) 1,440,172 NET LOSS BEFORE INCOME TAXES (4,125,194 ) - (4,125,194 ) (146,528 ) (249,359 ) (395,887 ) Income tax expense - - - - (134,986 ) (134,986 ) NET LOSS $ (4,125,194 ) $ - $ (4,125,194 ) $ (146,528 ) $ (384,345 ) $ (530,873 )
Lease, Cost [Table Text Block]	March 31, Lease costs (discontinued operations) Classification on the Statements of Operations 2023 2022 Discontinued operations: Finance leases - amortization of ROU assets Loss from discontinued operations $ - $ 116,024 Finance leases - interest on lease liabilities Loss from discontinued operations - 301,796 Operating leases Loss from discontinued operations - - Total lease cost, discontinued operations $ - $ 417,820

Note 5 - Notes Payable and Li_2

Note 5 - Notes Payable and Line of Credit (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Debt [Table Text Block]	As of March 31, 2023 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (as amended), current portion (Note 5) $ - $ - $ - 6% Convertible promissory notes payable (Note 6) 560,000 - 560,000 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 - 325,000 6% Convertible note payable due July 1, 2022 (Note 6) 50,000 - 50,000 6% Convertible promissory notes payable due September 30, 2023 (Note 6) 197,000 (9,475 ) 187,525 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (31,755 ) 218,245 0% Note Payable dated October 23, 2017 (as amended), long term portion (Note 5) 55,307 - 55,307 Total short-term notes and convertible notes payable $ 1,437,307 $ (41,230 ) $ 1,396,077 As of March 31, 2022 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (as amended), current portion (Note 5) $ 54,330 $ - $ 54,330 6% Convertible promissory notes payable (Note 6) 560,000 - 560,000 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 - 325,000 6% Convertible note payable due July 1, 2022 (Note 6) 50,000 (1,765 ) 48,235 Total short-term notes and convertible notes payable $ 989,330 $ (1,765 ) $ 987,565 6% Convertible promissory notes payable due September 30, 2023 (Note 6) $ 197,000 $ (26,254 ) $ 170,746 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (73,235 ) 176,765 0% Note Payable dated October 23, 2017 (as amended), long term portion (Note 5) 49,797 - 49,797 Total long term convertible notes payable classified as continuing operations $ 496,797 $ (99,489 ) $ 397,308

Note 8 - Income Taxes (Tables)

Note 8 - Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2023 2022 Tax expense/(benefit) computed at U.S. statutory rates $ (182,405 ) $ 691,042 Increases (decreases) in taxes resulting from: IRC Section 280E - 132,063 Other permanent items 9,246 5,526 Change in valuation allowance (756,430 ) 579,861 Adjustments to valuation of deferred tax assets 929,589 (1,408,492 ) Tax return true-up - 58,277 Total provision for income taxes - 58,277 Penalties and interest on prior year tax liabilities 61,960 76,709 Total income tax expense 61,960 $ 134,986
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2023 2022 Deferred tax assets: Stock based compensation $ 3,147,724 $ 3,144,084 Net operating loss carryforward 10,934,127 10,816,588 Impairment of long-lived assets 635,250 - Depreciation and Amortization expense (1,369 ) (1,369 ) Other temporary items (209,714 ) (209,714 ) Total deferred tax assets 14,506,018 13,749,589 Less valuation allowance (14,506,018 ) (13,749,589 ) Net deferred tax asset $ - $ -

Note 9 - Capital Transactions (

Note 9 - Capital Transactions (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants Outstanding Number of Shares Exercise Price Outstanding at March 31, 2021 85,843,036 Warrants issued 2,095,333 0.10 Warrants exercised (9,697,146 ) $0.01 - $0.03 Warrants expired/cancelled (3,116,550 ) 0.60 Outstanding at March 31, 2022 75,124,673 Warrants issued 56,835,004 0.10 Warrants exercised - Warrants expired/cancelled) (9,201,000 ) $0.08 - $0.10 Outstanding at March 31, 2023 122,758,677

Note 10 - Employee Benefit Pl_2

Note 10 - Employee Benefit Plan (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended March 31, 2023 March 31, 2022 Weighted-average volatility - % 131 % Expected term (in years) - % 10 % Risk-free interest rate - % 1.42 %
Schedule of Stock Options Roll Forward [Table Text Block]	Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Employee options and warrants Options Price $ Life (years) Value ($) Outstanding at March 31, 2021 17,733,334 $ 0.11 6.80 $ 172,000 Granted - Exercised - Forfeited - Outstanding at March 31, 2022 17,733,334 $ 0.11 5.80 $ - Fully vested and expected to vest at March 31, 2022 17,733,334 $ 0.11 Exercisable at March 31, 2022 15,566,668 $ 0.12 Granted - Exercised - Forfeited - Outstanding at March 31, 2023 17,733,334 $ 0.11 4.80 $ - Fully vested and expected to vest at March 31, 2023 17,733,334 $ 0.11 Exercisable at March 31, 2023 17,733,334 $ 0.11 Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Nonemployee options Options Price $ Life (years) Value ($) Outstanding at March 31, 2021 5,883,000 $ 0.14 8.11 $ - Granted 600,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2022 6,483,000 $ 0.13 7.31 $ - Fully vested and expected to vest at March 31, 2022 6,483,000 $ 0.13 Exercisable at March 31, 2022 6,483,000 $ 0.13 Granted - Exercised - Forfeited - Outstanding at March 31, 2023 6,483,000 $ 0.13 6.31 $ - Fully vested and expected to vest at March 31, 2023 6,483,000 $ 0.13 Exercisable at March 31, 2023 6,483,000 $ 0.13

Note 13 - Sale of Membership _2

Note 13 - Sale of Membership Interests in Nevada Subsidiaries (Tables)	12 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Deconsolidation [Table Text Block]	December 31, 2021 Cash payments received, including advancements of $400,000 $ 1,648,772 8% Note Receivable due December 31, 2024 3,025,000 Extinguishment of debt and accrued interest due to purchasers and purchasers' affiliates 2,612,854 Extinguishment of accrued management fees due to purchaser 850,000 Total consideration 8,136,626 Carrying amount of assets 7,130,159 Carrying amount of liabilities (4,199,741 ) Net assets deconsolidated 2,930,418 GAIN ON DECONSOLIDATION $ 5,206,208

Note 1 - Background and Natur_2

Note 1 - Background and Nature of Operations (Details Textual) - USD ($)								9 Months Ended		12 Months Ended
	Mar. 27, 2023	Dec. 31, 2021	Dec. 14, 2021	Aug. 10, 2020	Mar. 24, 2020	Nov. 27, 2019	Oct. 23, 2017	Dec. 31, 2021	Dec. 31, 2021	Mar. 31, 2023	Mar. 31, 2022	Mar. 10, 2023	Mar. 09, 2023	Aug. 15, 2019	Apr. 08, 2018	Mar. 31, 2018
Common Stock, Shares Authorized (in shares)										950,000,000	950,000,000	950,000,000	600,000,000	600,000,000	400,000,000	250,000,000
Notes Reduction										$ 0	$ 2,612,854
Proceeds from Divestiture of Interest in Consolidated Subsidiaries										$ 0	1,648,772
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage				0%			0%
Receivable with Imputed Interest, Effective Yield (Interest Rate)							20.30%
GB Sciences Nopah, LLC [Member]
Sale of Stock, Percentage of Ownership						100%
Sale of Interest, Percentage of Ownership				100%
Noncash or Part Noncash Divestiture, Amount of Consideration Received				$ 312,315
Nevada Subsidiaries [Member]
Sale of Stock, Percentage of Ownership					100%
Teco Subsidiaries [Member]
Sale of Stock, Consideration Received on Transaction					$ 8,000,000
Notes Receivable, Interest Rate					8%
GB Sciences Nopah, LLC [Member]
Notes Reduction	$ 504,167			237,668
Extinguishment of Debt, Amount								$ 3,462,854	$ 3,462,854
Sale of Stock, Percentage of Ownership before Transaction		100%
Proceeds from Divestiture of Interest in Consolidated Subsidiaries									1,648,772		1,648,772
Proceeds From Divestiture of Business, Advances Received		$ 400,000						400,000	400,000
Financing Receivable, after Allowance for Credit Loss, Total	$ 2,520,833	3,025,000						$ 3,025,000	$ 3,025,000		$ 60,500
Receivable with Imputed Interest, Effective Yield (Interest Rate)								8%	8%
GB Sciences Nopah, LLC [Member] | Accounts Payable Due to Affiliate of the Purchaser [Member]
Extinguishment of Debt, Amount		$ 74,647	$ 74,647	$ 74,647

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Retained Earnings (Accumulated Deficit)	$ (108,705,315)	$ (104,580,122)
Working Capital (Deficit)	(4,450,202)	(3,607,638)
Net Cash Provided by (Used in) Operating Activities	(1,526,861)	(1,866,154)
Cash Provided by (Used in) Operating Activities, Discontinued Operations	$ 0	$ (87,772)

Note 3 - Basis of Presentatio_2

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)	12 Months Ended
	Mar. 31, 2023 USD ($) shares	Mar. 31, 2022 USD ($) shares
Short-Term Investments	$ 0	$ 0
Impairment of Intangible Assets, Finite-Lived	2,374,261	0
Finite-Lived Intangible Assets, Net	42,819	2,222,074
Research and Development Expense	$ 490,291	$ 821,321
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares	167,252,135	118,594,624
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)		3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)		8 years
Licensed Patents [Member]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$ 0
UNITED STATES
Indefinite-Lived Intangible Assets, Pending, Number	10
Non-US [Member]
Indefinite-Lived Intangible Assets, Pending, Number	35
Patents [Member]
Impairment of Intangible Assets, Finite-Lived	$ 2,374,261
Finite-Lived Intangible Assets, Number		6
Amortization of Intangible Assets	61,660	$ 70,488
Finite-Lived Intangible Assets, Net	$ 42,819
Patents [Member] | GBS Global Biopharma, Inc [Member]
Finite-Lived Intangible Assets, Number		4
Licensed Patents [Member]
Finite-Lived Intangible Assets, Number		2

Note 4 - Discontinued Operati_3

Note 4 - Discontinued Operations (Details Textual) - Discontinued Operations [Member] - USD ($)	37 Months Ended
	Jan. 05, 2023	Mar. 31, 2023	Mar. 31, 2022
Accounts Receivable, after Allowance for Credit Loss, Total		$ 0	$ 0
Deposits Assets, Noncurrent	$ 0
Lessee, Finance Lease, Discount Rate	11.50%
Debt Instrument, Interest Rate, Stated Percentage	8%
Line of Credit Facility, Maximum Borrowing Capacity	$ 470,000
Proceeds from Lines of Credit	485,000
Line of Credit Facility, Maximum Borrowing Capacity, Increased	15,000
Long-Term Line of Credit	485,000
Interest Payable	$ 49,211

Note 4 - Discontinued Operati_4

Note 4 - Discontinued Operations - Discontinued Operations (Details) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021
Cash	$ 109,912	$ 233,893
Prepaid and other current assets	199,592	93,933
TOTAL CURRENT ASSETS	309,504	327,826
Finite-Lived Intangible Assets, Net	42,819	2,222,074
TOTAL ASSETS	352,323	2,549,900
Accrued interest	346,806	384,769
Accrued liabilities	75,628	9,627
Convertible notes payable, net	1,396,077	987,565
Income tax payable	958,455	896,495
TOTAL CURRENT LIABILITIES	4,759,706	3,935,464
Convertible notes payable, net	0	397,308
TOTAL LIABILITIES	4,759,706	4,332,772
Sales revenue	0	0
Cost of goods sold	0	0
Gross profit (loss)	0	0
General and administrative expenses	1,672,281	1,868,734
Gain on extinguishment of debt	0	22,405
Gain on deconsolidation	0	5,206,208	$ 5,206,208
Interest expense	(178,652)	(474,768)
Loss on impairment of note receivable	0	(3,025,000)
Loss on impairment of capitalized patent costs	(2,374,261)	0
Loss on disposal	0	(15,639)
Other income	100,000	9,000
Total other income/(expense)	(2,452,913)	1,722,206
Income tax expense	0	0
NET LOSS	0	(384,345)
Continuing Operations [Member]
Cash	109,912	233,893
Prepaid and other current assets	199,592	93,933
TOTAL CURRENT ASSETS	309,504	327,826
Finite-Lived Intangible Assets, Net	42,819	2,222,074
TOTAL ASSETS	352,323	2,549,900
Accounts payable	1,982,740	1,657,008
Accrued interest	346,806	384,769
Accrued liabilities	75,628	9,627
Notes and convertible notes payable, net	935,000	987,565
Convertible notes payable, net	461,077	0
Income tax payable	958,455	896,495
TOTAL CURRENT LIABILITIES	4,759,706	3,935,464
Convertible notes payable, net	0	397,308
TOTAL LIABILITIES	4,759,706	4,332,772
Sales revenue	0	0
Cost of goods sold	0	0
Gross profit (loss)	0	0
General and administrative expenses	1,672,281	1,868,734
LOSS FROM OPERATIONS	(1,672,281)	(1,868,734)
Gain on extinguishment of debt	0	22,405
Gain on deconsolidation	0	5,206,208
Interest expense	(178,652)	(474,768)
Loss on impairment of note receivable	0	(3,025,000)
Loss on impairment of capitalized patent costs	(2,374,261)	0
Loss on disposal	0	(15,639)
Other income	100,000	9,000
Total other income/(expense)	(2,452,913)	1,722,206
NET LOSS BEFORE INCOME TAXES	(4,125,194)	(146,528)
Income tax expense	0	0
NET LOSS	(4,125,194)	(146,528)
Discontinued Operations [Member]
Cash	0	0
Prepaid and other current assets	0	0
TOTAL CURRENT ASSETS	0	0
Finite-Lived Intangible Assets, Net	0	0
TOTAL ASSETS	0	0
Accounts payable	0	0
Accrued interest	0	0
Accrued liabilities	0	0
Notes and convertible notes payable, net	0	0
Convertible notes payable, net	0	0
Income tax payable	0	0
TOTAL CURRENT LIABILITIES	0	0
Convertible notes payable, net	0	0
TOTAL LIABILITIES	0	0
Sales revenue	0	3,369,812
Cost of goods sold	0	(3,072,622)
Gross profit (loss)	0	297,190
General and administrative expenses	0	264,515
LOSS FROM OPERATIONS	0	32,675
Gain on extinguishment of debt	0	0
Gain on deconsolidation	0	0
Interest expense	0	(302,923)
Loss on impairment of note receivable	0	0
Loss on impairment of capitalized patent costs	0	0
Loss on disposal	0	0
Other income	0	20,889
Total other income/(expense)	0	(282,034)
NET LOSS BEFORE INCOME TAXES	0	(249,359)
Income tax expense	0	(134,986)
NET LOSS	0	(384,345)
Segment, Continuing and Discontinued Operations [Member]
Cash	109,912	233,893
Prepaid and other current assets	199,592	93,933
TOTAL CURRENT ASSETS	309,504	327,826
Finite-Lived Intangible Assets, Net	42,819	2,222,074
TOTAL ASSETS	352,323	2,549,900
Accounts payable	1,982,740	1,657,008
Accrued interest	346,806	384,769
Accrued liabilities	75,628	9,627
Notes and convertible notes payable, net	935,000	987,565
Convertible notes payable, net	461,077	0
Income tax payable	958,455	896,495
TOTAL CURRENT LIABILITIES	4,759,706	3,935,464
Convertible notes payable, net	0	397,308
TOTAL LIABILITIES	4,759,706	4,332,772
Sales revenue	0	3,369,812
Cost of goods sold	0	(3,072,622)
Gross profit (loss)	0	297,190
General and administrative expenses	1,672,281	2,133,249
LOSS FROM OPERATIONS	(1,672,281)	(1,836,059)
Gain on extinguishment of debt	0	22,405
Gain on deconsolidation	0	5,206,208
Interest expense	(178,652)	(777,691)
Loss on impairment of note receivable	0	(3,025,000)
Loss on impairment of capitalized patent costs	(2,374,261)	0
Loss on disposal	0	(15,639)
Other income	100,000	29,889
Total other income/(expense)	(2,452,913)	1,440,172
NET LOSS BEFORE INCOME TAXES	(4,125,194)	(395,887)
Income tax expense	0	(134,986)
NET LOSS	$ (4,125,194)	$ (530,873)

Note 4 - Discontinued Operati_5

Note 4 - Discontinued Operations - Lease Costs Recorded in the Company's Financial Statements (Details) - Discontinued Operations [Member] - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Finance leases - amortization of ROU assets	$ 0	$ 116,024
Finance leases - interest on lease liabilities	0	301,796
Operating leases	0	0
Total lease cost, discontinued operations	$ 0	$ 417,820

Note 5 - Notes Payable and Li_3

Note 5 - Notes Payable and Line of Credit (Details Textual)							1 Months Ended	9 Months Ended		12 Months Ended
	Mar. 04, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 14, 2021 USD ($)	Dec. 29, 2020 USD ($)	Aug. 10, 2020 USD ($)	Oct. 23, 2017 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Mar. 27, 2023 USD ($)	Jul. 24, 2020 USD ($)
Gain (Loss) on Extinguishment of Debt, Total										$ 0	$ 22,405
Leslie Bocskor [Member] | Unpaid Severance Compensation [Member]
Related Party Transaction, Amounts of Transaction										48,820
GB Sciences Nopah, LLC [Member]
Receivable with Imputed Interest, Effective Yield (Interest Rate)								8%	8%
Extinguishment of Debt, Amount								$ 3,462,854	$ 3,462,854
Financing Receivable, after Allowance for Credit Loss, Total		$ 3,025,000					$ 60,500	3,025,000	3,025,000		60,500		$ 2,520,833
GB Sciences Nopah, LLC [Member] | Accounts Payable Due to Affiliate of the Purchaser [Member]
Extinguishment of Debt, Amount		74,647	$ 74,647		$ 74,647
Teco Subsidiaries [Member] | The July 24 Note [Member]
Financing Receivable, after Allowance for Credit Loss, Total		1,025,000		$ 3,025,000				1,025,000	1,025,000
Increase (Decrease) in Notes Receivable, Current				975,000
Notes Receivable, Maximum Allowed Prepayments On Note				325,000
Disposal Group, Including Discontinued Operation, Consideration				$ 4,000,000
Gain (Loss) on Amendment to Line of Credit												$ (650,000)
Notes Receivable, Additional Advances									50,000
Interest and Debt Expense, Total									12,510
The July 24 Note [Member] | Revolving Credit Facility [Member]
Debt Instrument, Interest Rate, Stated Percentage														8%
Line of Credit Facility, Maximum Borrowing Capacity														$ 500,000
The July 24 Note [Member] | Teco Subsidiaries [Member]
Financing Receivable, after Allowance for Credit Loss, Total														$ 4,000,000
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding														3
Promissory Note [Member]
Debt Instrument, Face Amount							496,797			1,437,307	$ 496,797
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage					0%	0%
Debt Instrument, Face Amount						$ 700,000
Debt Instrument, Term (Year)						3 years
Debt Instrument, Present Value						$ 521,067
Receivable with Imputed Interest, Effective Yield (Interest Rate)						20.30%
Debt Instrument, Unamortized Discount, Total						$ 178,933
Notes Payable, Current, Total		$ 369,445						$ 369,445	$ 369,445
Notes Payable, Principal and Interest	$ 201,532
Notes Payable, Principal and Interest, After Modified Terms	179,127
Repayment of Notes Payable	75,000
Debt Instrument, Monthly Payment, Amount	$ 5,000
Debt Instrument, Interest Rate, Stated Percentage, After Term Modification	8%
Gain (Loss) on Extinguishment of Debt, Total							$ 22,405
Notes Payable, Current and Noncurrent										55,307
Interest Payable										$ 691
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | Membership Interest Purchase Agreement for Sale of Interest in GB Sciences Nopah, LLC [Member]
Debt Instrument, Principal Balance After Reduction Upon Close of Disposition					$ 190,272
Nevada Medical Marijuana Production License Agreement [Member]
Payments to Acquire License						$ 500,000
Nevada Medical Marijuana Production License Agreement [Member] | Production License [Member]
Ownership of License						100%
Nevada Medical Marijuana Production License Agreement [Member] | Cultivation License [Member]
Ownership of License						100%

Note 5 - Notes Payable and Li_4

Note 5 - Notes Payable and Line of Credit - Summary of Notes and Convertible Notes Payable (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Oct. 23, 2017
Discount, short-term notes payable	$ 0	$ (99,489)
Discount, short-term notes payable	(41,230)	(1,765)
Promissory Note [Member]
Short-Term Notes Payable	1,437,307	496,797
Discount, short-term notes payable	(41,230)	(99,489)
Carrying value, long-term notes payable	1,396,077	397,308
The 0% Note Payable Dated October 23, 2017 [Member] | Convertible Debt [Member]
Short-Term Notes Payable		49,797
Discount, short-term notes payable		0
Carrying value, long-term notes payable		49,797
The 0% Note Payable Dated October 23, 2017 [Member] | Note Payable [Member]
Short-Term Notes Payable	55,307
Carrying value, long-term notes payable	55,307
The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]
Short-Term Notes Payable			$ 700,000
The 6 % Note Payable Dated December 31, 2023 [Member] | Convertible Debt [Member]
Short-Term Notes Payable		50,000
Carrying value, short-term notes payable		48,235
Discount, short-term notes payable		(1,765)
The 6 % Note Payable Dated September 30, 2023 [Member] | Convertible Debt [Member]
Short-Term Notes Payable	197,000	197,000
Discount, short-term notes payable	(9,475)	(26,254)
Carrying value, long-term notes payable	187,525	170,746
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Convertible Debt [Member]
Short-Term Notes Payable	250,000
Discount, short-term notes payable	(31,755)
Carrying value, long-term notes payable	218,245
The 6% Convertible Note Payable Due December 31, 2023 [Member] | Convertible Debt [Member]
Short-Term Notes Payable		250,000
Discount, short-term notes payable		(73,235)
Carrying value, long-term notes payable		176,765
Note Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Short-Term Notes Payable	0
Carrying value, short-term notes payable	0
Convertible Notes Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Short-Term Notes Payable		54,330
Carrying value, short-term notes payable		54,330
Discount, short-term notes payable		0
Convertible Notes Payable [Member] | The 6% Note Payable Due November 30, 2018 [Member]
Short-Term Notes Payable	560,000	560,000
Carrying value, short-term notes payable	560,000	560,000
Discount, short-term notes payable		0
Convertible Notes Payable [Member] | The 6% Notes Payable Due January 18, 2022 [Member]
Short-Term Notes Payable	325,000	325,000
Carrying value, short-term notes payable	325,000	325,000
Discount, short-term notes payable		0
Convertible Notes Payable [Member] | The 6% Notes Payable Due July 1, 2022 [Member]
Short-Term Notes Payable	50,000
Carrying value, short-term notes payable	50,000
Discount, short-term notes payable	$ 0
Promissory Note [Member]
Short-Term Notes Payable		989,330
Carrying value, short-term notes payable		987,565
Discount, short-term notes payable		$ (1,765)

Note 6 - Convertible Notes (Det

Note 6 - Convertible Notes (Details Textual)			1 Months Ended		3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Jan. 20, 2022 USD ($)	Feb. 28, 2019 USD ($) $ / shares	Jul. 31, 2017 USD ($) $ / shares	Mar. 31, 2017 USD ($) $ / shares	May 31, 2017 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 18, 2020 USD ($) $ / shares	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) Rate
Class of Warrant or Right, Issued During Period (in shares) | shares								56,835,004	2,095,333
Amortization of Debt Discount (Premium)								$ 60,024	$ 356,340
Proceeds from Convertible Debt								0	50,000
Convertible Notes Payable, Current								1,396,077	987,565
Convertible Notes Payable, Noncurrent								0	397,308
Discontinued Operations, Disposed of by Sale [Member] | Teco Sale [Member]
Notes and Accrued Interest Payable, Exchange Reduction, Percentage (Rate) | Rate										110%
Disposal Group, Including Discontinued Operation, Consideration										$ 4,000,000
Increase (Decrease) Liability Due from Exchange Reduction, Percentage (Rate) | Rate										10%
Increase (Decrease) Liability Due from Exchange Reduction, Value										$ 125,686
Convertible Debt [Member]
Convertible Notes Payable, Total	$ 560,000
Interest Expense, Debt, Total								195,770
Interest Payable								39,185
Debt Instrument, Debt Default, Amount								$ 1,060,000
Repayments of Convertible Debt	$ 500,000
Warrants Issued in March 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Number of Warrants				4,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 0.60	$ 0.60
Warrants and Rights Outstanding, Term (Year)				3 years	3 years
Class of Warrant or Right, Issued (in shares) | shares					8,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares					1
Warrants Issued In March 2017 and July 2017 Convertible Note Offerings [Member]
Debt Instrument, Convertible, Number of Warrants			4,000
Class of Warrant or Right, Issued During Period (in shares) | shares								788,000
Warrants Related to July 2017 Convertible Note Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 0.65			$ 0.60
Warrants and Rights Outstanding, Term (Year)						3 years
Class of Warrant or Right, Issued (in shares) | shares						28,804,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares						1
Warrants Issued in September 30, 2023, Convertible Note Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 0.10
Warrants and Rights Outstanding, Term (Year)								3 years
Warrants and Rights Outstanding								$ 13,396
March And July 2017 Convertible Note Offering [Member] | Convertible Debt [Member]
Debt Instrument, Unamortized Discount, Total								46,886
Debt Instrument, Convertible, Beneficial Conversion Feature								33,490
Interest Expense, Debt, Total								28,599
Amortization of Debt Discount (Premium)								16,779
Interest Payable								67,972
The 6 % Convertible Note Payable Dated December 31, 2023 [Member]
Debt Instrument, Interest Rate, Stated Percentage							6%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares							$ 0.05
The 6 % Convertible Note Payable Dated December 31, 2023 [Member] | Three Investors [Member]
Debt Instrument, Face Amount							$ 625,000
The 6 % Convertible Note Payable Mature in December 2021 [Member] | Three Investors [Member]
Debt Instrument, Face Amount							375,000
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Three Investors [Member]
Debt Instrument, Face Amount							250,000
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Convertible Debt [Member]
Debt Instrument, Face Amount								250,000
The 6 Percent Convertible Note Payable Issued With In Money Conversion Features [Member]
Debt Instrument, Face Amount							425,000
Debt Instrument, Unamortized Discount, Total							81,250		6,500
Debt Instrument, Convertible, Beneficial Conversion Feature							347,000
Interest Expense, Debt, Total								83,737
Amortization of Debt Discount (Premium)								43,245
Proceeds from Convertible Debt							$ 543,750		50,000
Convertible Notes Payable, Current								1,396,077
Convertible Notes Payable, Noncurrent								$ 41,230
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount Per Note				$ 1,000
Debt Instrument, Interest Rate, Stated Percentage				6%
Debt Instrument, Face Amount					$ 2,000,000
Debt Instrument, Term (Year)					3 years
Debt Instrument, Unamortized Discount, Total					$ 1,933,693
Debt Instrument, Convertible, Beneficial Conversion Feature					904,690
Debt Instrument, Convertible, Discount, Fair Value of Warrants					$ 1,029,003
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments				4,000	8,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares				$ 0.25
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount Per Note			$ 1,000
Debt Instrument, Face Amount						$ 7,201,000
Debt Instrument, Term (Year)			3 years			3 years
Debt Instrument, Unamortized Discount, Total						$ 7,092,796
Debt Instrument, Convertible, Beneficial Conversion Feature						3,142,605
Debt Instrument, Convertible, Discount, Fair Value of Warrants						$ 3,950,191
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments			4,000			28,804,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares			$ 0.25
Convertible Notes Payable [Member] | March And July 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares								$ 0.10
Debt Instrument, Extended Amount								$ 197,000
Convertible Notes Payable, Total								$ 1,257,000
Promissory Note [Member]
Debt Instrument, Face Amount									989,330
Short-term Debt, Total									$ 987,565
Promissory Note [Member] | July 2017 Convertible Note Offering [Member]
Debt Instrument, Interest Rate, Stated Percentage			6%
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage		8%
Debt Instrument, Face Amount		$ 1,500,000
Interest Payable										144,994
Short-term Debt, Total										$ 1,111,863
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | GB Sciences, Nevada, LLC [Member] | Collateral Pledged [Member]
Noncontrolling Interest, Ownership Percentage by Parent		100%
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments		8,823,529
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares		$ 0.17

Note 8 - Income Taxes (Details

Note 8 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2018
Effective Income Tax Rate Reconciliation, Percent	0%	1.80%
Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations	$ 61,960	$ 134,986
Income Tax Reconciliation, Prior Year Tax Penalties	41,313
Income Tax Reconciliation, Accrued Interest on Prior Year Tax Liabilities	20,647
Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount			$ 178,727	$ 506,145
Taxes Payable, Current	958,455
Income Tax Reconciliation, Cumulative Accrued Penalties and Interest	273,594
Operating Loss Carryforwards	51,260,036	52,067,273
Operating Loss Carryforwards, Subject to Expiration	$ 34,481,122
Operating Loss Carryforwards, Not Subject to Expiration		$ 17,026,440

Note 8 - Income Taxes - Reconci

Note 8 - Income Taxes - Reconciliation of Effective Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Tax expense/(benefit) computed at U.S. statutory rates	$ (182,405)	$ 691,042
IRC Section 280E	0	132,063
Other permanent items	9,246	5,526
Change in valuation allowance	(756,430)	579,861
Adjustments to valuation of deferred tax assets	929,589	(1,408,492)
Tax return true-up	0	58,277
Total provision for income taxes	0	58,277
Penalties and interest on prior year tax liabilities	61,960	76,709
Total income tax expense	$ 61,960	$ 134,986

Note 8 - Income Taxes - Deferre

Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022
Stock based compensation	$ 3,147,724	$ 3,144,084
Net operating loss carryforward	10,934,127	10,816,588
Impairment of long-lived assets	635,250	0
Depreciation and Amortization expense	(1,369)	(1,369)
Other temporary items	(209,714)	(209,714)
Total deferred tax assets	14,506,018	13,749,589
Less valuation allowance	(14,506,018)	(13,749,589)
Net deferred tax asset	$ 0	$ 0

Note 9 - Capital Transactions_2

Note 9 - Capital Transactions (Details Textual) - USD ($)				1 Months Ended	9 Months Ended	12 Months Ended
	Sep. 09, 2022	May 09, 2022	Mar. 01, 2022	Mar. 31, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Aug. 25, 2022	Jun. 30, 2022	Jul. 18, 2021	Apr. 01, 2020
Proceeds from Issuance of Private Placement						$ 221,650
Class of Warrant or Right, Issued During Period (in shares)						56,835,004	2,095,333
Proceeds from Warrant Exercises						$ 0	$ 138,728
Induced Dividend from Warrant Exercises							$ 0
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share)
Share-based Payment Arrangement, Expense						$ 17,333	$ 60,667
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total						$ 0
Share-Based Payment Arrangement, Nonemployee [Member]
Share-based Payment Arrangement, Expense							$ 28,800
Minimum [Member]
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)							$ 0.01
Maximum [Member]
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)							$ 0.03
Share-Based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense							$ 60,667
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total				$ 17,333			$ 17,333
Share-Based Payment Arrangement, Option [Member] | Seven Persons [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Authorized, Percentage of Common Shares Issued and Outstanding								13%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price, Percentage of Value Per Share								80%
Warrants Issued to Investors in Private Placements [Member]
Number of Warrant Received, Per Unit (in shares)		1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1								1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.10			$ 0.10					$ 0.10
Warrants and Rights Outstanding, Term (Year)					5 years				5 years	3 years
Stock Issued During Period, Shares, New Issues (in shares)					56,835,004
Class of Warrant or Right, Issued During Period (in shares)					56,835,004
Class of Warrant or Right, Exercises in Period (in shares)			7,601,813				2,095,333
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)				$ 0.01			$ 0.03
Proceeds from Warrant Exercises				$ 76,068			$ 56,394
Brokerage Fees for Issuance of Common Stock and Warrants							6,266
Induced Dividend from Warrant Exercises							163,017
Class of Warrant or Right, Exercised During Period, Intrinsic Value							62,660
Class of Warrant or Right, Issued During Period, Fair Value							$ 100,357
Exercise of Warrants for Stock, Shares (in shares)							2,088,667
Warrants Issued to Investors in Private Placements [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)											$ 0.03
Warrants Issued to Investors in Private Placements [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)											$ 0.05
Compensation Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)					1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 0.03
Warrants and Rights Outstanding, Term (Year)					5 years
Class of Warrant or Right, Issued During Period (in shares)					5,416,834
Class of Warrant or Right, Fair Value Assumption, Exercise Price (in dollars per share)					$ 0.0273
Warrants and Rights Outstanding					$ 147,879
Warrants Issued to Researcher as Compensation [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1			1
Warrants and Rights Outstanding, Term (Year)				10 years			10 years
Class of Warrant or Right, Issued During Period (in shares)							600,000
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share)							$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)				$ 0.048			$ 0.048
Private Placement [Member]
Sale of Units, Maximum Units Allowed in Private Placement	$ 2,000,000	$ 565,000
Sale of Units, Price Per Unit (in dollars per share)		$ 0.03
Number of Common Stock Received, Per Unit (in shares)		1

Note 9 - Capital Transactions -

Note 9 - Capital Transactions - Warrant Activity (Details) - $ / shares	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Outstanding (in shares)	75,124,673	85,843,036
Warrants issued (in shares)	56,835,004	2,095,333
Warrants issued, exercise price (in dollars per share)
Warrants exercised (in shares)	0		(9,697,146)
Warrants expired/cancelled (in shares)	(9,201,000)	(3,116,550)
Outstanding (in shares)	122,758,677	75,124,673	85,843,036
Minimum [Member]
Warrants exercised, exercise price (in dollars per share)		$ 0.01
Warrants expired/cancelled, exercise price (in dollars per share)	0.08
Maximum [Member]
Warrants exercised, exercise price (in dollars per share)		0.03
Warrants expired/cancelled, exercise price (in dollars per share)	$ 0.10	$ 0.60

Note 10 - Employee Benefit Pl_3

Note 10 - Employee Benefit Plan (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Sep. 17, 2021	Oct. 25, 2018	Jun. 30, 2015	Feb. 06, 2008
Share-based Payment Arrangement, Expense	$ 17,333	$ 60,667
Class of Warrant or Right, Expense	17,333	60,667
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	0
Restricted Stock [Member]
Share-based Payment Arrangement, Expense	$ 0
Share-Based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense		60,667
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 17,333
GB Sciences, Inc. 2007 Amended Stock Option Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)						4,500,000
The 2014 Equity Compensation Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)					8,500,000
GB Sciences, Inc 2018 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				10,000,000
The 2021 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	20,000,000		20,000,000

Note 10 - Employee Benefit Pl_4

Note 10 - Employee Benefit Plan - Assumptions (Details) - Share-Based Payment Arrangement, Option [Member]	12 Months Ended
	Mar. 31, 2022
Weighted-average volatility	131%
Expected term (in years) (Year)	10 years
Risk-free interest rate	1.42%

Note 10 - Employee Benefit Pl_5

Note 10 - Employee Benefit Plan - Option Activity (Details) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Fully vested and expected to vest, options (in shares)	17,733,334
Fully vested and expected to vest, weighted average exercise price (in dollars per share)	$ 0.11
Exercisable, options (in shares)	17,733,334
Exercisable, weighted average exercise price (in dollars per share)	$ 0.11
Share-Based Payment Arrangement, Employee [Member]
Outstanding, options (in shares)	17,733,334	17,733,334
Outstanding, weighted average exercise price (in dollars per share)	$ 0.11	$ 0.11
Outstanding, weighted average remaining contractual life (Year)	4 years 9 months 18 days	5 years 9 months 18 days	6 years 9 months 18 days
Outstanding, aggregate intrinsic value	$ 0	$ 0	$ 172,000
Granted, options (in shares)	0	0
Granted, weighted average exercise price (in dollars per share)
Exercised, options (in shares)	0	0
Exercised, weighted average exercise price (in dollars per share)
Forfeited, options (in shares)	0	0
Forfeited, weighted average exercise price (in dollars per share)
Fully vested and expected to vest, options (in shares)		17,733,334
Fully vested and expected to vest, weighted average exercise price (in dollars per share)		$ 0.11
Exercisable, options (in shares)		15,566,668
Exercisable, weighted average exercise price (in dollars per share)		$ 0.12
Outstanding, options (in shares)	17,733,334	17,733,334	17,733,334
Outstanding, weighted average exercise price (in dollars per share)	$ 0.11	$ 0.11	$ 0.11
Share-Based Payment Arrangement, Nonemployee [Member]
Outstanding, options (in shares)	6,483,000	5,883,000
Outstanding, weighted average exercise price (in dollars per share)	$ 0.13	$ 0.14
Outstanding, weighted average remaining contractual life (Year)	6 years 3 months 21 days	7 years 3 months 21 days	8 years 1 month 9 days
Outstanding, aggregate intrinsic value	$ 0	$ 0
Granted, options (in shares)	0	600,000
Granted, weighted average exercise price (in dollars per share)		$ 0.05
Exercised, options (in shares)	0	0
Forfeited, options (in shares)	0	0
Fully vested and expected to vest, options (in shares)	6,483,000	6,483,000
Fully vested and expected to vest, weighted average exercise price (in dollars per share)	$ 0.13	$ 0.13
Exercisable, options (in shares)	6,483,000	6,483,000
Exercisable, weighted average exercise price (in dollars per share)	$ 0.13	$ 0.13
Outstanding, options (in shares)	6,483,000	6,483,000	5,883,000
Outstanding, weighted average exercise price (in dollars per share)	$ 0.13	$ 0.13	$ 0.14

Note 12 - Related Party Trans_2

Note 12 - Related Party Transactions (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Repayments of Related Party Debt	$ 48,820	$ 575,000
Officers and Directors [Member]
Repayments of Related Party Debt		84,913
Related Party [Member]
Accounts Payable, Current	120,911	0
Related Party [Member] | Officers and Directors [Member]
Line of Credit Facility, Remaining Borrowing Capacity		$ 0
Related Party [Member] | Chief Executive Officer [Member]
Accounts Payable, Current	108,816
Related Party [Member] | President and Director [Member]
Accounts Payable, Current	$ 12,095

Note 13 - Sale of Membership _3

Note 13 - Sale of Membership Interests in Nevada Subsidiaries (Details Textual)								9 Months Ended		12 Months Ended
	Mar. 27, 2023 USD ($)	Dec. 31, 2021 USD ($)	Dec. 14, 2021 USD ($)	Aug. 10, 2020 USD ($)	Mar. 24, 2020 USD ($)	Nov. 27, 2019	Oct. 23, 2017	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Notes Reduction										$ 0		$ 2,612,854
Proceeds from Divestiture of Interest in Consolidated Subsidiaries										0		1,648,772
Deconsolidation, Gain (Loss), Amount										$ 0		5,206,208	$ 5,206,208
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage				0%			0%
Receivable with Imputed Interest, Effective Yield (Interest Rate)							20.30%
GB Sciences Nopah, LLC [Member]
Sale of Stock, Percentage of Ownership						100%
Noncash or Part Noncash Divestiture, Amount of Consideration Received				$ 312,315
Nevada Subsidiaries [Member]
Sale of Stock, Percentage of Ownership					100%
Teco Subsidiaries [Member]
Sale of Stock, Consideration Received on Transaction					$ 8,000,000
Notes Receivable, Interest Rate					8%
GB Sciences Nopah, LLC [Member]
Notes Reduction	$ 504,167			237,668
Extinguishment of Debt, Amount								$ 3,462,854	$ 3,462,854
Sale of Stock, Percentage of Ownership before Transaction		100%
Sale of Stock, Percentage of Ownership after Transaction		0%
Proceeds from Divestiture of Interest in Consolidated Subsidiaries									1,648,772			1,648,772
Proceeds From Divestiture of Business, Advances Received		$ 400,000						400,000	400,000				400,000
Financing Receivable, after Allowance for Credit Loss, Total	2,520,833	3,025,000						$ 3,025,000	$ 3,025,000		$ 60,500	$ 60,500	$ 3,025,000
Receivable with Imputed Interest, Effective Yield (Interest Rate)								8%	8%
Deconsolidation, Gain (Loss), Amount									$ 5,206,208
Quarterly Interest Only Payments on Note Receivable, Years											1	1
Number of Quarterly Principal and Interest Payments on Note Receivable											7	7
Note Receivable, Quarterly Principal and Interest Installment												$ 201,774
Final Payment, Principal and Interest Payments Due on Note Receivable											$ 2,014,225	2,014,225
Note Receivable, Interest Only, Monthly											$ 60,500
Asset Impairment Charges, Total												$ 3,025,000
Notes Receivable, Initial Payment	100,000
Note Receivable, Additional Payment Amount	1
Note Receivable, Reduction of Principal Amount	5.0416
Notes Receivable, Additional Aggressive Amount Payments	$ 500,000
GB Sciences Nopah, LLC [Member] | Accounts Payable Due to Affiliate of the Purchaser [Member]
Extinguishment of Debt, Amount		$ 74,647	$ 74,647	$ 74,647

Note 13 - Sale of Membership _4

Note 13 - Sale of Membership Interests in Nevada Subsidiaries - Gain on Deconsolidation (Details) - USD ($)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021
Cash payments received, including advancements of $400,000	$ 0	$ 1,648,772
8% Note Receivable due December 31, 2024	0	3,025,000
Extinguishment of debt and accrued interest due to purchasers and purchasers' affiliates	0	2,612,854
Extinguishment of accrued management fees due to purchaser	0	850,000
GAIN ON DECONSOLIDATION	$ 0	$ 5,206,208	$ 5,206,208
Nevada Subsidiaries [Member]
Cash payments received, including advancements of $400,000			1,648,772
8% Note Receivable due December 31, 2024			3,025,000
Extinguishment of debt and accrued interest due to purchasers and purchasers' affiliates			2,612,854
Extinguishment of accrued management fees due to purchaser			850,000
Total consideration			8,136,626
Carrying amount of assets			7,130,159
Carrying amount of liabilities			(4,199,741)
Net assets deconsolidated			$ 2,930,418

Note 14 - Subsequent Events (De

Note 14 - Subsequent Events (Details Textual) - USD ($)		12 Months Ended
	Apr. 01, 2023	Mar. 31, 2023	Mar. 31, 2022
Proceeds from Convertible Debt		$ 0	$ 50,000
Proceeds from Warrant Exercises		$ 0	$ 138,728
Subsequent Event [Member]
Proceeds from Warrant Exercises	$ 80,025
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	8,002,500
Subsequent Event [Member] | Three Convertible Notes Payable [Member]
Proceeds from Convertible Debt	$ 150,000
Debt Instrument, Interest Rate, Stated Percentage	6%
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 0.03